APP and Alzheimer disease: Both 5-HT1BR agonists and 5-HT4R agonists may shift the cleavage of APP to the production of sAPPα, thus inhibiting amyloid formation, further reducing the hyperexcitability of CA1 pyramidal neurons and improving cognitive function in AD mice [51, 53].